

## Inhibition of DNase I Enzyme with Nickel(II) Triphenylphosphine Complexes Incorporating Tridentate Schiff Base Ligands in Vitro

Şükriye GÜVELİ \*1

<sup>1</sup>Department of Chemistry, Engineering Faculty, Istanbul University-Cerrahpaşa, 34320, Avcilar, Istanbul, Turkey

**Abstract:** The nickel(II) complexes containing with ONS chelating 3-methoxy-salicylaldehyde-N<sup>4</sup>-R thiosemicarbazones (R:-H<sub>2</sub>,-propyl) and triphenylphosphine coligands have been synthesized. The structures of Ni(II)-centered metal complexes were approved by means of analytical and spectroscopic data. The solid-state structure of complex 2 bearing PPh3 as co-ligand was clarified by single crystal X-ray crystallography, which revealed square planar geometry around Ni(II) ion. The potential of these complexes to inhibit the DNase I enzyme, which uses DNA as a substrate, was investigated *in vitro*. The results revealed that the compounds inhibited the DNase enzyme directly and/or indirectly (by masking of DNA molecules) at  $\geq 0.1 \mu g/mL$  concentrations *in vitro*.

**Keywords:** Nickel(II); thiosemicarbazone; X-ray; DNase I.

Submitted: October 19, 2018. Accepted: December 25, 2018.

**Cite this:** Güveli Ş. Inhibition of DNase I Enzyme with Nickel(II) Triphenylphosphine Complexes Incorporating Tridentate Schiff Base Ligands in Vitro. JOTCSA. 2018;5(3):1403–10.

**DOI:** <u>http://dx.doi.org/10.18596/jotcsa.472530.</u>

\*Corresponding author. E-mail: <a href="mailto:sguveli@istanbul.edu.tr">sguveli@istanbul.edu.tr</a>.

## INTRODUCTION

The reaction of thiosemicarbazide and an aldehyde or ketone results in thiosemicarbazone Thiosemicarbazones compounds. are an important class of chelating ligands which contain nitrogen and sulfur donor atoms and have extensive applications in various fields such as medicine, industry, analytical and organic processing (1-4). Mixed-thiosemicarbazones complexes bearing seconder ligand play essential roles in biological processes like activation of enzymes metals (5-6). Particularly by thiosemicarbazone-based nickel(II) complexes have shown significant antiviral (7), antibacterial (8) and anticancer activities (9). Investigations on interactions of DNA and thiosemicarbazone molecules have attracted significant attention over the last years (10). The square planar Ni(II)thiosemicarbazone complexes were reported to have DNA interaction and topoisomerase II inhibition activity (11-13).

Deoxyribonuclease I, was the first enzyme to be recognized as specific for DNA, binds to the small

groove of DNA and is often used as an enzymatic tool to study the interaction of DNA and proteins (14,15). DNases play a significant role in alimentary canal digestion and in pathogenesis of diverse diseases and apoptosis, while DNase inhibitors could modify or control those activities. Determining molecules that are able to cleaving/binding DNA has drawn great attention because of their important use in nanotechnology, therapeutic and biotechnology applications (16, 17).

Binding affinity in CT-DNA and protein and cytotoxicity activity against cancer cell lines HeLa, A549 and HepG2 of Ni(II) complexes consisting of 4-methoxysalicylaldehyde-N<sup>4</sup>-Rthiosemicarbazone (R: H, Me, Et, Ph) and PPh<sub>3</sub> were investigated by Prabhakaran et al. The results showed that the complexes have important binding ability and cytotoxicity activity in contrast of their ligands. The binding affinity towards DNA and protein is decreased in order of  $C_2H_5>CH_3>H>C_6H_5$  unlike in order of cytotoxic activity (11). Another paper of Prabhakaran is on DNA topoisomerase II inhibition activity of

#### **RESEARCH ARTICLE**

nickel(II) complexes consisted of salicylaldehyde-N<sup>4</sup>-R (R: Me, Ph)/2-hydroxynaphthaldehyde-N<sup>4</sup>-R (R: Me)-thiosemicarbazone and PPh<sub>3</sub>. The activity is decreased in order of [Ni(Nap-Me-tsc)(PPh<sub>3</sub>)]>[Ni(Sal-Ph-tsc)(PPh<sub>3</sub>)]>[Ni(Sal-Me-tsc)(PPh<sub>3</sub>)].

In our previous study, two nickel complexes incorporating tridentate Schiff bases derived from

3-methoxy salicylaldehyde with triphenylphosphine were synthesized and characterized by various spectroscopic data (7). In this paper, the complexes **1**,**2** (Figure 1.) were firstly investigated for DNase I enzyme inhibition and the crystal structure of the complex **2** was performed by single-crystal diffraction.



Figure 1. The chemical diagrams of complexes (1, 2).

#### **EXPERIMENTAL SECTION**

#### Synthesis

The nickel complexes were prepared by the literature method as follows (7, 12). Reactions of the solution of thiosemicarbazone ligands (1 mmol) in dichloromethane (10 mL) with the solution of dichlorobistriphenylphosphine nickel(II) (1 mmol) in 10 mL absolute ethanol in

equivalent amounts were resulted by giving the tetra-coordinated Ni(II) complexes (Figure 1). The structure of Ni(II) complexes were characterized by means of analytical and spectroscopic data (7). The complex 2, was in the form of fine crystals, soluble in alcohols and chlorinated hydrocarbons. Recrystallization of complex 2 was resulted in the composition of [Ni(L)(PPh<sub>3</sub>)].



Figure 2. Crystal structure of the complex 2.

#### X-ray crystallography

The data of intensity of the complex was recorded on a Bruker D8 VENTURE diffractometer equipped with PHOTON100 detector at 304 K temperature using graphite- monochromated Mo Ka radiation (k = 0.71073 Å) by applying the multi-scan method. SHELXS program of the SHELXTL-1997 (18) software is used to solve of the structure which is refined by full-matrix least-squares methods with SHELXL-2014/7 (19, 20). Absorption corrections were performed using SADABS (21). The intensity data were integrated by SAINT software package using a wide-frame algorithm (22). All H atoms were placed in calculated positions and treated using a riding model, fixing the bond lengths at 0.82, 0.93, 0.97, 0.97 and 0.96 Å for NH, aromatic CH, methine, methylene, methyl atoms, respectively. The details of the data collection and structure solution are collected in Table 1.

# Deoxyribonuclease I (DNase I) inhibition activity

DNase I enzyme (Sigma-D4227), isolated from bovine pancreas, was used to determine the effects of complexes on DNase enzyme activity in vitro. The DNase enzyme was dissolved in a buffer containing 10 mM Tris (pH:7.5), 10 mM CaCl<sub>2</sub>, and 50% (v/v) glycerin with  $\sim$ 10U/µl and stored at -20 °C. The pHKP-Luc plasmid, purified by the plasmid DNA isolation kit from *Escherichia* coli DH5a cells, was used as the DNA molecule. Plasmid DNA was obtained from K.Turan (23). The reaction was carried out in 15 µL of DNase I buffer (10 mM tris, 2.5 mM MqCl<sub>2</sub>, 0.5 mM CaCl<sub>2</sub>, pH 7.5) containing 2 m units of DNase, 1 µg of plasmid DNA and 0.1, 0.01 or 0.001 µg of complex by allowing to stand for 20 minutes at 37 °C. At the end of the period, DNase I enzyme was inactivated by heating the reaction mixtures at 75 °C for 10 min. To clarify the enzymatic digestion of plasmid DNAs, the reaction mixtures were analysed with agarose gel electrophoresis. For this purpose, the samples were mixed with x 6 concentrated gel loading buffer at the 1:5 ratio and applied to 1% agarose gel. Electrophoresis was completed in 25 minutes under a constant voltage of 100 V in TAE buffer. DNA was visualized with a UV transilluminator and photographed.

## DNase I inhibition studies

The potential inhibition activity of the complexes DNase Ι was investigated bv on ael electrophoresis (Figure 4). It is observed that almost entire DNase I activity were inhibited by the complexes at the concentration of  $0.1 \,\mu\text{g/mL}$ . In the case of the diluted complex concentration of 0.01 and 0.001  $\mu$ g/mL. It is revealed that the activity of the enzyme decreased. It is suggested that the inhibition efficiency of the complexes on DNase I enzyme protects the DNA structure. The observed inhibition activities against DNase I could be associated with the coordinatively unsaturated square planar geometry of the metal

### **RESULTS AND DISCUSSION**

#### **Crystal structure studies**

The reaction of [Ni(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] and the thiosemicarbazones in the same ratio gave yields, the diamagnetic Ni(II)-complexes 1, 2 containing PPh<sub>3</sub> co-ligand. The complexes were coordinated to Ni(II) by giving two protons from thiosemicarbazone via phenolic -OH and thiol group. In to approve the definite structure of the complex **2**, crystallographic analysis has been carried out. ORTEP-3 (19) drawing of the complex is illustrated in Figure 2, whilst the bond angles/lengths are presented in Table 2. Complex **2** includes the dibasic form of the ligand which acts as tridentate ligand by the nitrogen, sulfur and oxygen atoms resulting in the formation of six and five-membered chelate ring with O-Ni-N and S-Ni-N bite angles of 95(3)° and 86.6(2)°, respectively. The triphenylphosphine group forms the fourth coordination of Ni(II). The C-S bonddistance is 1.745(9) Å, revealing that thiolate form of thiosemicarbazone bound to metal. The P(1)-Ni-N(3) and S(1)-Ni-O(1) bond-angles deviate remarkably from 180° which shows that is significant distortion in NiSNOP core around nickel atom. Packing diagram of the complex 2 is shown in Figure 3. According to the figure, no hydrogen-bonds or important intermolecularinteractions in the structure were observed.

center which causes binding the DNA to the available vacant sites. Another possibility is that the complexes can directly and/or indirectly inhibit the DNase I enzyme. Regarding, Prabhakaran et al. has investigated DNA topoisomerase II inhibition activity of nickel(II)-PPh<sub>3</sub> complexes containing the thiosemicarbazones coordinated in ONS fashion. This study showed increase in the electron deficiency on metal centre and the formation of coordinative unsaturated square planar geometry was attributed to the binding of topoisomerase enzyme to the metal centre (13).

Parameter	2	
CCDC depository	1873557	
Color/shape	Brown / Rod	
Chemical formula	$C_{30}H_{30}N_3NiO_2PS$	
Formula weight	586.31	
Temperature (K)	304	
Wavelength (Å)	0.71073 (Mo K <i>a</i> )	
Crystal system	Monoclinic	
Space group	P 21	
Unit cell parameters		
a, b, c (Å)	11.546(4), 8.050(2), 15.287(6)	
a, β, γ (°)	90, 97.490 (11), 90	
Volume (Å <sup>3</sup> )	1408.7(9)	
Ζ	2	
D <sub>calc</sub> (g/cm <sup>3</sup> )	1.382	
$\mu$ (mm <sup>-1</sup> )	0.852	
Absorption correction	Multi-scan	
T <sub>min</sub> , T <sub>max</sub>	0.931, 0.983	
F <sub>000</sub>	612	
Crystal size (mm <sup>3</sup> )	$0.020 \times 0.070 \times 0.200$	
Diffractometer	Bruker D8 VENTURE	
Measurement method	multi scan	
Index ranges	$-13 \le h \le 13, -8 \le k \le 9, -18 \le l \le 18$	
heta range for data collection (°)	2.37 to 25.00	
Reflections collected	10369	
Independent reflections	4699	
Observed reflections	2684	
R <sub>int</sub>	0.0658	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data/restraints/parameters	4699/398/349	
Goodness-of-fit on $F^2$	1.033	
Final R indices $[I > 2\sigma(I)]$	$R_1 = 0.0542, wR_2 = 0.1050$	
R indices (all data)	$R_1 = 0.0956, wR_2 = 0.1186$	
$\Delta \rho_{\rm max}, \Delta \rho_{\rm min}$ (e/Å <sup>3</sup> )	0.777, -0.440	

**Table 1** Crystal data and structure refinement parameters for complex 2.

Bond lengths (Å)		Bond angles (°)	
Ni1—P1	2.216(2)	P1-Ni1-S1	90.28(9)
Ni1—S1	2.137(2)	P1-Ni1-01	88.32(17)
Ni1-01	1.865(5)	P1-Ni1-N3	171.0(2)
Ni1—N3	1.882(6)	S1-Ni1-01	178.08(19)
S1-C4	1.745(9)	S1-Ni1-N3	86.6(2)
O1-C9	1.313(9)	01-Ni1-N3	95.0(3)
N2—N3	1.402(9)	S1-C4-N1	117.9(7)
N1-C3	1.473(14)	S1-C4-N2	123.6(7)
N1-C4	1.345(12)	N1-N2-C9	113.1(2)
N2-C4	1.286(11)	N2-C9-N3	119.8(3)
N3—C5	1.305(10)	N2-N3-C5	113.8(7)
		N3-C5-C6	127.5(8)
		C4-N3-C3	118.9(10)





Figure 3. Molecular packing of the complex 2.



**Figure 4**. The diagram of the agarose gel electrophoresis shows the inhibition of DNase I enzyme by Ni(II) complexes **1**, **2**: lanes 1-3 (for complex **1**): 0.1  $\mu$ g/mL; 0.01  $\mu$ g/mL; 0.001  $\mu$ g/mL, respectively; lane 4 (DM): DNase I enzyme with DMSO control; lanes 5-7 (for complex **2**): 0.1  $\mu$ g/mL; 0.01  $\mu$ g/mL; 0.001  $\mu$ g/mL, respectively; lane 8 (DM): DNase I enzyme with DMSO control; lane 9 (Enz): plasmid DNA incubated with DNase I; lane 10 (C): pHKP-Luc plasmid DNA alone.

#### CONCLUSION

The nickel-PPh<sub>3</sub> complex **2** of 3-methoxysalicylaldehyde-N<sup>4</sup>-propyl-thiosemicarbazone was identified by X-ray crystallographic techniques, which confirmed the dibasic forms  $(L^{2-})$  of propyl-substituted in the nickel centered chelates. The thiosemicarbazone complexes containing N4-long chain alkyl substituent are few in literatures. The synthesized compounds have a slightly distorted square planar geometry involving the thiosemicarbazone, coordinated via ONS mode. The DNase I enzyme inhibition of Ni(II)-thiosemicarbazone complexes, which uses DNA as a substrate, was observed in electrophoresis *in vitro*. studies for the first time. The asset of electron withdrawing groups in the coordinated thiosemicarbazones causes the increment in the electron lack on the metal. Thus, it is thought that the coordinative unsaturated square-planar geometry maybe in charge of the binding of DNA to nickel(II).

## ACKNOWLEDGMENTS

This research was supported by Research Fund of Istanbul University (BYP-2018-27646). I dedicate this paper to Dr. Bahri ÜLKÜSEVEN and Dr. Tülay BAL-DEMİRCİ, the mentors of my research career. I'm grateful to Dr. Kadir TURAN, from Faculty of Pharmacy Marmara University, for assistance with DNase I inhibition studies and this useful discussions.

## REFERENCES

1. Lobana TS, Kumari P, Hundal G, Butcher RJ. Metal derivatives of N1-substituted thiosemicarbazones with divalent metal ions (Ni, Cu): Synthesis and structures. Polyhedron. 2010;29(3):1130-36.

2. Padhye S, Kauffman GB. Transition Metal Complexes of Semicarbazones and Thiosemicarbazones. Coord. Chem. Rev.1985;63:127-60.

3. Jiang ZG, Lebowitz MS, Ghanbari HA. Neuroprotective activity of 3 aminopyridine-2carboxaldehydethiosemicarbazone (PAN-811), a cancer therapeutic agent. CNS Drug Rev. 2006;12(1):77-90.

4. Güveli S, Kılıç-Cıkla I, Ülküseven B, Yavuz M, Bal-Demirci T. 5-Methyl-2-hydroxyacetophenone-S-methyl-thiosemicarbazone and its nickel-PPh<sub>3</sub> complex. Synthesis, characterization, and DFT calculations. J. Mol. Struct. 2018;1173:366-74.

5. Ekennia AC, Onwudiwe DC, Ume C, Ebenso EE. Mixed ligand complexes of N-Methyl-N-phenyl dithiocarbamate: Synthesis, characterisation, antifungal activity, and solvent extraction studies of the ligand. Bioinorgan. Chem. Appl. 2015;2015:1-10.

6. Güveli Ş, Bal-Demirci T, Ülküseven B, Özdemir N. Supramolecular nickel complex based on thiosemicarbazone. Synthesis, transfer hydrogenation and unexpected thermal behavior. Polyhedron. 2016;110: 188-96.

7. Güveli S, Turan K, Ülküseven B. Nickel(II)-PPh<sub>3</sub> complexes with ONS and ONN chelating thiosemicarbazones: synthesis and inhibition potential on influenza A viruses. Turk. J. Chem. 2018;42;371-84.

8. Pahontu E, Fala V, Gulea A, Poirier D, Tapcov V, Rosu T. Synthesis and characterization of some new Cu(II), Ni(II) and Zn(II) complexes with

salicylidene thiosemicarbazones: antibacterial, antifungal and in vitro antileukemia activity. Molecules. 2013;18(8):8812-36.

9. Belicchi Ferrari M, Bisceglie F, Pelosi G, Sassi M, Tarasconi P, Cornia M, Capacchi S, Albertini R, Pinelli S. Synthesis, characterization and X-ray structures of new antiproliferative and proapoptotic natural aldehyde thiosemicarbazones and their nickel(II) and copper(II) complexes. J. Inorg. Biochem. 2002;90(3-4):113-26.

10. Bal Demirci T, Congur G, Erdem A, Erdem-Kuruca S, Ozdemir N, Akgun-Dar K, et al. Iron(III) and nickel(II) complexes as potential anticancer agents: synthesis, physicochemical and structural properties, cytotoxic activity and DNA interactions. New J. Chem. 2015;39(7):5643-53.

11. Umadevi C, Kalaivani P, Puschmann H, Murugan S, Mohana PS, Prabhakaran R. Substitutional impact on biological activity of new water soluble Ni(II) complexes: Preparation, spectral characterization, X-ray crystallography, DNA/protein binding, antibacterial activity and in vitro cytotoxicity. Journal of Photochemistry & Photobiology, B: Biology. 2017;167:45–57.

12. Kalaivani P, Saranya S, Poornima P, Prabhakaran R, Dallemer F, Vijaya Padma V, Natarajan K. Biological evaluation of new nickel(II) metallates: Synthesis, DNA/protein binding and mitochondrial mediated apoptosis in human lung cancer cells (A549) via ROS hypergeneration and depletion of cellular antioxidant pool. Eur. J. Med. Chem. 2014;82:584-599.

13. Prabhakaran R, Sivasamy R, Angayarkanni J, Huang R, Kalaivani P, Karvembu R, Dallemer F, Natarajan K. Topoisomerase II inhibition activity of new square planar Ni(II) complexes containing N-substituted thiosemicarbazones: Synthesis, spectroscopy, X-ray crystallography and electrochemical characterization. Inorg. Chim. Acta. 2011;374(1):647-653.

14. Nadano D, Yasuda T, and Kishi K. Measurement of Deoxyribonuclease I Activity in Human Tissues and Body Fluids by a Single Radial Enzyme-Diffusion Method. Clin. Chem. 1993;39(3):448-52.

15. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of deoxyribonuclease I. Proc. Natl. Acad. Sci. U.S.A. 1974;71(6):4742-46.

16. Baranovskii AG, Buneva VN, Nevinsky GA. Human deoxyribonucleases. Biochem. Mosc. 2004;69(6):587-601.

17. Kolarevic A, Yancheva D, Kocic G, Smelcerovic A. Deoxyribonuclease inhibitors.

European Journal of Medicinal Chemistry. 2014;88:101-11.

18. Sheldrick G. SHELXS-97, Program for Crystal Structure Solution, Univ. Göttingen, Germany. 1997.

19. Sheldrick GM SHELXL2014/1 Programs for the Solution and Refinement of Crystal Structures. University of Göttingen. 2014.

20. Sheldrick GM. A short history of SHELX. Acta

Crystallographica Section A Foundations of Crystallography. 2008;64(1):112–22.

21. Sheldrick GM. University of Göttingen, Germany. 1996.

22. Saint P. Bruker AXS Inc., Madison, Wisconsin, USA. 2012.

23. Çağlayan E, Turan K. The effects of DNA methyl transferases on antiaging klotho gene expression. Turk. J. Biol. 2016;40(4):797-806.

1406